Cabazitaxel was FDA approved this year for the treatment of hormone refractory prostate cancer. In a Phase III study, patients with hormone and docetaxel Foretinib 849217-64-7 refractory metastatic prostate cancer were addressed with cabazitaxel or mitoxantrone, patients in the experimental arm had statistically increased median OS compared to those in the mitoxantrone arm and median PFS was doubled within the cabazitaxel party. However, the majority of males experienced grade 3 neutropenia, and a fraction experienced febrile neutropenia, and all degrees PN, consequently careful patient selection and growth factor support to prevent prolonged neutropenia might be justified, particularly in high-risk populations including the elderly. In conclusion, paclitaxel and docetaxel remain applied widely in the administration of various malignan?cies despite their drawbacks, such as, bad drug solubility, toxicities and emergence Skin infection of drug resistance. Ongoing drug development efforts are in place searching for new less toxic and more active analogs with new remedies to overcome these issues, but so far the majority of these novel compounds didn’t present the clinical superiority within the parent com?pounds. Presently, Abraxane and cabazitaxel would be the recent FDA-APPROVED taxane additions to your medical antineoplastic drug armamentarium. Moreover, the recent successful clini?cal introduction of novel nontaxane microtubule targeting chemotherapy agents such as epothilones and eribulin is likely to help expand restrict the development of novel taxanes and formulations. As recently since the start of 21st-century, metastatic castration resistant prostate cancer had a bleak prognosis. The available treatments, such as radiotherapy, boneseeking isotopes, bisphosphonates, chemotherapy, corticosteroids and analgesics, offered palliation of symptoms, but no improvement in survival. 1 Previously 8 years, the outlook has changed dramatically. First, the landmark TAX327 MAPK pathway cancer demo of docetaxel demonstrated that, despite previous experience, 2 mCRPC was responsive to chemotherapy in terms of individual survival. . 1 Then, in 2010, after 6 years with no treatment offering a survival benefit in the post docetaxel setting, phase III data on cabazitaxel showed that patients could derive further survival benefit from second-line chemotherapy. 3 In 2011, the hormonal agent abiraterone was also reported to boost survival in patients previously treated with docetaxel. 4 Both cabazitaxel and abiraterone are now actually accepted for use in Canada for the treating mCRPC that has advanced during or after docetaxel based chemotherapy. In addition, evidence is accumulating from studies of other agents, perhaps not yet approved in Canada, that offer a survival benefit in mCRPC.